Document ID: chunk:federal_register_of_legislation:F2024L01337:front:0:p3
Version: federal_register_of_legislation:F2024L01337
Segment Type: other
Provision Reference: 
Character Range: 5862–9239

decreased ankle or forefoot flexibility;
         4.           forefoot varus;
         5.           lateral ankle joint instability;
 2.           having one of the following systemic arthritic diseases at the time of clinical onset or clinical worsening:
         1.           ankylosing spondylitis;
         2.           Behcet syndrome;
         3.           enteropathic spondyloarthropathy (arthritis associated with inflammatory bowel disease);
         4.           gout;
         5.           pseudogout (calcium pyrophosphate dihydrate) or crystal-induced arthropathy from the deposition of calcium hydroxyapatite or calcium oxalate;
         6.            psoriatic arthropathy
         7.           reactive arthritis;
         8.           rheumatoid arthritis; or
         9.             undifferentiated spondyloarthropathy;
 3.           having chronic renal failure within the 10 years before clinical onset or clinical worsening as indicated by:
         1.           a glomerular filtration rate of less than 15 mL/min/1.73 m2 for a period of at least 3 months; or
         2.           undergoing chronic dialysis for renal failure;
 4.           being treated with a fluoroquinolone antibiotic within the 30 days before clinical onset or clinical worsening;
Note: Examples of fluoroquinolone antibiotics include ciprofloxacin, moxifloxacin, norfloxacin and ofloxacin.
 1.           being treated with a glucocorticoid drug as specified before clinical onset or clinical worsening;
Note: being treated with a glucocorticoid drug as specified is defined in the Schedule 1 - Dictionary.
 1.           having a glucocorticoid injection into the Achilles tendon, in the region of the Achilles tendon or in the retrocalcaneal bursa, before the rupture of the Achilles tendon;
Note: rupture of the Achilles tendon can constitute clinical onset or clinical worsening of Achilles tendinopathy.
 1.       being treated with an aromatase inhibitor for at least 4 weeks within the 1 year before clinical onset or clinical worsening;
Note: Examples of aromatase inhibitors include anastrozole, exemestane and letrozole.
 1.       having a Body Mass Index (BMI) of 30 or greater at the time of  clinical onset or clinical worsening;
Note: BMI is defined in the Schedule 1 – Dictionary.
 1.       having diabetes mellitus at the time of clinical onset or clinical worsening;
 2.       inability to obtain appropriate clinical management for Achilles tendinopathy before clinical worsening.
 1.            Relationship to service
         1.           The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.
         2.           The clinical worsening aspects of factors set out in section 9 apply only to material contribution to, or aggravation of, Achilles tendinopathy where the person's Achilles tendinopathy was suffered or contracted before or during (but did not arise out of) the person's relevant service.
 2.            Factors referring to an injury or disease covered by another Statement of Principles
In this Statement of Principles:
 1.           if a factor referred to in section 9 applies in relation to a person; and
 2.           that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;